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REDUCTION OF ACUTE GVHD IN UNRELATED HEMATOPOIETIC STEM
CELL TRANSPLANTATION BY CO-INFUSION OF HAPLOIDENTICAL BONE
MARROW AS THE THIRD PARTY CELLS
Zhao, Y.-L., Gao, Y.-Q., Xiong, M., Zhang, W.-J., Zhou, J.-R., Sun, Y.,
Zhang, Y.-C., Da, W.-M., S.-Q., JiLuD.-P. Beijing Daopei Hospital,
Beijing, China
Acute graft versus host disease (aGVHD) is one of main causes for
morbidity and mortality in unrelated donor hematopoietic stem cell
transplantation (URT). Our previousmurine and clinical studies had
demonstrated that the third party cells could reduce the incidence
and degree of aGVHD. In haploidentical hematopoietic stem cell
transplantation, unrelated cord blood as the third party cells could
significantly reduce the incidence of aGVHD and 100-day trans-
plant-related mortality (Lu DP et al. ASH 2008). In this perspective
pilot study, the safety and efficacy of co-infusion of haploidentical
bone marrow (haplo-BM) in URT were investigated. FromOctober
2008 to June 2010, 18 patients with hematological malignancies who
received URT with haplo-BM co-infusion in Beijing Dao-Pei Hos-
pital were enrolled. Median age of the patients was 25 (9-39) years
old. Diagnosis included AML (n 5 8), ALL (n 5 4), CML (n 5 5)
and SAA(n 5 1). Twelve of 17 patients with malignances were in
CR1 or CP1 before transplant. HLA 10/10 matched was in 6 cases,
9/10matched in 5, and 8/10matched in 7. Conditioning was BU/CY
or CY/TBI plus ATG (5mg/kgX 4, Fresenius). Cyclosporine,MTX,
and MMF were used for GVHD prophylaxis. Haplo-BM (1 ml/kg)
was infused right after URT. Haplo-BM co-infusion had no any
side events. All 18 patients had hematopoietic reconstitution. Full
unrelated donor chimerism was detected by STR PCR in all patients
one month after transplant, and no engraftment of haplo-BM was
found. By October 2010, the median follow-up time was 12.5(3-
23) months. Only one patient developed grade IV aGVHD at day
30, and died of infection 8 months post-URT. The estimated one
year OS and LFS are 92.3%. The other 17 patients had no grade
II-IV aGVHD and are free of their primary diseases. Our prelimi-
nary results show that haplo-BM co-infusion as the third party cell
is safe, convenient and inexpensive. It could reduce the incidence
of aGVHD in URT.386
CLOFARABINE 6 FLUDARABINE AND IV BUSULFAN WITH ALLOGENEIC
STEM CELL TRANSPLANTATION FOR ADVANCED MYELOID LEUKEMIA
(ML) AND MDS
Andersson, B.S.1, Valdez, B.C.1, Thall, P.F.2, Wang, X.2, Worth, L.L.3,
Popat, U.1, Alousi, A.1, Hosing, C.1, Jones, R.B.1, Shpall, E.J.1, de
Lima, M.1, Champlin, R.E.1 1UT MD Anderson Cancer Center,Table 1. Simple and Adjusted Models of Mortality, Hospitalization,
HCT by Pre-transplant Respiratory Virus Status.
Outcome Respiratory Virus HR (
Overall survival No virus (N5338)
All viruses (N5115) 2.1 (1
Group 1 (n571) 2.0 (1
Group 2 (n544) 2.1 (0
Days (
Days alive and out of hospital No virus (N5338)
All viruses (N5115) -9.8 (-1
Group 1 (n571) -9.8 (-1
Group 2 (n544) -9.7 (-1
HR (9
Bronchoscopy incidence No virus (N5338)
All viruses (N5115) 1.6 (1
Group 1 (n571) 1.3 (0
Group 2 (n544) 2.1 (1
*All outcomes adjusted for disease risk. Also adjusted for 1age, stem cell sourHouston, TX; 2UT MD Anderson Cancer Center, Houston, TX; 3UT
MD Anderson Cancer Center, Houston, TX
Clofarabine (Clo), a later generation nucleoside analog (NA), has
much improved antileukemic effects, and it shows synergistic activity
when combined with Fludarabine (Flu) and Busulfan (Bu) under
controlled in vitro conditions. We investigated combinations of
[Clo6Flu] with IV Bu as pretransplant conditioning in patients
with advanced myeloid leukemia and MDS.
Methods: Patients were adaptively randomized based on day +30
disease- and chimerism status: Arm I: Clo:Flu 10:30 mg/m2, Arm
II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV: Clo only at
40 mg/m2. The Clo and Flu were infused over 1 hr each once daily
for 4 days, on each day Bu was given over 3 hr targeting an average
daily AUC of 6,000 mMol-min. GVHD-prophylaxis was tacroli-
mus+mini-MTX. Recipients of unrelated or one Ag-mism related
donor cells received rabbit-ATG at a total dose of 4 mg/kg.
Results: There were 36 males, 20 females, median age was 45 yrs
(range 6-59). 46 had AML (ind. failure: 15, chemo-refr. relapse:
11, untr. relapse: 7, CR2+CR2p: 10, high-risk CR1+CR1p: 3). 23
had intermediate-, one had good- and 21 poor-prognosis cytogenet-
ics, 1 was unknown. 10 had CML (BC: 2, second AP: 4, and late CP
4). 25/56 (44%) had related donors (BM: 6, PBPC: 19), and 31 (55%)
unrelated donors (BM:16, PBPC:15). All patients engrafted. All pa-
tients had 100% (64-100) donor-derived DNA in the T- and mye-
loid-cell populations by day +100. The adaptive randomization
allocated most patients to Arm III, (Clo 30 mg/m2, Flu 10 mg/m2),
consistent with in vitro observed synergy of [Clo+Flu]. 28/33
(85%) transplanted with active AML and 8 of 10 with CML achieved
CR. Median overall survival is 16 months (range 1-45), one-year
overall and event-free survival are 58% and 43%. There were 2 treat-
ment-related deaths by day +100 (4%), one infectious and one of
GVHD.Grade 2-3 mucositis was seen in 80% of patients, but no se-
rious hepatic, renal, or neuro-toxicities were encountered.
We conclude that 1) the immunosuppressive capability of Clofar-
abine supports allogeneic progenitor cell engraftment, 2) Clo6Flu
with IV Bu is safe and efficacious conditioning therapy 3) the adap-
tive randomization favoring Arm III (Clo 30 mg/m2 and Flu 10 mg/
m2) agreed with previously observed in vitro synergy of [Clo+Flu].
Additional patients and longer follow-up are warranted to evaluate
the combined [Clo+Flu] with IV Bu in pretransplant therapy.387
CLINICAL OUTCOMES ASSOCIATED WITH PRE-TRANSPLANTATION RE-
SPIRATORY VIRUS INFECTIONS
Campbell, A.P.1,2,3, Minerich, E.L.1,3, Guthrie, K.A.3, Farney, R.M.3,
Kuypers, J.2,3, Englund, J.A.1,2,3, Boeckh, M.2,3 1Seattle Children’s
Hospital, Seattle, WA; 2University of Washington, Seattle, WA; 3Fred
Hutchinson Cancer Research Center, Seattle, WAand Bronchoscopy Incidence During the First 100 Days After
Unadjusted Adjusted*
95% CI) p-value HR (95% CI)1 p-value
1.0 - 1.0 -
.1 – 3.7) 0.02 2.0 (1.1 – 3.8) 0.02
.0 – 4.0) 0.05 1.9 (1.0 – 4.0) 0.07
.9 – 4.9) 0.07 2.2 (0.9 – 5.2) 0.07
95% CI) p-value Days (95% CI)2 p-value
0 - 0 -
5.3, -4.2) <0.001 -8.7 (-13.9, -3.6) <0.001
6.6, -3.1) 0.004 -8.5 (-14.7, -2.3) 0.008
7.9, -1.4) 0.02 -9.2 (-16.8, -1.5) 0.02
5% CI) p-value HR (95% CI)3 p-value
1.0 - 1.0 -
.0 – 2.5) 0.06 1.4 (0.9 – 2.2) 0.17
.7 – 2.3) 0.43 1.1 (0.6 – 2.1) 0.69
.1 – 3.8) 0.02 1.8 (1.0 – 3.4) 0.05
ce, donor type; 2stem cell source, transplant type; and 3age.
S294 Poster Session IIBackground:The outcomes of patients infected with respiratory vi-
ruses prior to allogeneic hematopoietic cell transplantation (HCT)
are largely unknown. We sought to determine whether respiratory
virus detection before HCT influenced overall survival, days hospi-
talized, and incidence of bronchoscopy during the first 100 days after
HCT.
Methods: Pre-HCT and weekly post-HCT nasal washes were col-
lected from patients through day 100 between 12/2005 and 04/
2010. Nasal and bronchoalveolar lavage samples, if available, were
tested by PCR for respiratory syncytial virus (RSV), parainfluenza vi-
rus (PIV) types 1-4, influenza A&B (Flu), metapneumovirus (MPV),
adenovirus (AdV), rhinoviruses (RHV), coronaviruses (CoV), and
bocavirus (BoV). We analyzed outcomes between patients with
and without pre-transplant infections. We defined viruses associated
with less severe respiratory disease (RHV, CoV, BoV) as Group 1,
and those with more severe disease (RSV, PIV, Flu, MPV, AdV) as
Group 2. Hospitalization was analyzed as number of days alive and
not hospitalized.
Results:Respiratory viruses were detected in samples between 1 and
60 days (median 17 days) before HCT from 115 (25%) of 453 pa-
tients. Those with a respiratory virus detected were younger (p 5
0.002) and more likely to have high-risk underlying disease (p 5
0.009). In a multivariable model, patients with positive pre-HCT
samples had significantly worse survival and averaged nearly 10 fewer
days out of the hospital between day 1 and 100 (Table). Group 2 vi-
ruses were associated with increased incidence of undergoing bron-
choscopy.
Conclusion: One in 4 patients was infected with a respiratory virus
before HCT. The presence of a pre-HCT respiratory virus infection
was associated with increased mortality, prolonged hospitalization,
and increased pulmonary morbidity. Unfortunately, delay of HCT
is often not feasible and effective treatment is unavailable for most
respiratory viruses. These data emphasize the need for intensified
prevention of pre-HCT respiratory virus acquisition and improved
management strategies, including the development of new antiviral
agents.388
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(alloHSCT) IS UNDERUTILIZED IN MYELODYSPLASTIC SYNDROME
(MDS): A POPULATION-BASED CANADIAN PROVINCE EXPERIENCE
Kumar, R.1, Richardson, E.2, Khair, H.3, Paulson, K.1, Szwajcer, D.1,
Seftel, M.1, Rubinger, M.1, Musuka, C.4, Wall, D.1 1University of Man-
itoba, CancerCare Manitoba, Winnipeg, MB, Canada; 2CancerCare
Manitoba, Winnipeg, MB, Canada; 3CancerCare Manitoba, Winnipeg,
MB, Canada; 4University of Manitoba, Diagnostic Services of Manitoba,
Winnipeg, MB, Canada
Introduction: A recent decision withholding approval for HSCT
for Medicare beneficiaries with MDS prompted this study to inves-
tigate the utilization of allogeneic transplant in young patients (pts)
presenting withMDS. InManitoba (population 1.2 million) HSCTs
are performed in one center and there is no funding restriction for
eligible pts with MDS. There is a robust provincial cancer registry.
Methods: (1) We retrospectively studied a cohort of pts with MDS
in Manitoba to determine the number who underwent alloHSCT
compared to potentially eligible cases. Transplant eligibility was de-
fined as: (a) age # 65yr and (b) IPSS Int-2 and high risk groups, or
poor prognostic features such as: refractory cytopenias, blasts $
10%, high risk cytogenetics, therapy-related MDS and RCMD
with cytopenias (BBMT 2009; 15: 137-72 and BMT 2009; 43: 597-
609). (2) The Manitoba BMT (MBMT) registry was searched to de-
termine the number of alloHSCTs forMDS and other disorders per-
formed from 1991 to 2008.
Results: (1) In the two year period of 2006-2007 there were 80 inci-
dent cases of MDS or CMML (excluding RAEB-t) (Kumar et al Blood
2009; 114: Abstract#245). Of these, 23 pts (29%) were# 65 yrs of age;
9 of themwere considered ineligible for HSCT (6 - no poor prognos-
tic features, 2 - associated malignancy, 1- incomplete data). In the re-
maining 14 (18%), only 4 pts underwent alloHSCT and of these, 2
were transplanted after transformation and therapy for AML. The
median overall survival was 7 months (95% CI 3.6-12.2) for the 10
pts who were not transplanted (Table). AlloHSCT for MDS priorto leukemic transformation was done in only 14% (2/14) of eligible
pts. (2) The MBMT registry data over 18 yrs showed that 20 pts re-
ceived an alloHSCT for MDS or CMML, including 8 with RAEB-
t. As 18 of these 20 pts were residents of Manitoba, a mean of one al-
loHSCT for MDS per year was performed for the province. During
the same period, 277 alloHSCTswere carried out.MDS cases formed
7% of all alloHSCTs performed inManitoba, and 40%of theseMDS
pts had RAEB-t, now classified as AML.
Conclusion:Within the limitations of retrospective analysis, we es-
timate that only 18% of MDS patients were eligible for alloHSCT.
Moreover, alloHSCT has been under-utilized, as only 14% of these
eligible pts actually received alloHSCT prior to disease progression.
Earlier referrals to the BMT program may increase the number of
HSCTs. These observations may be useful in the planning of health
services for MDS.
Table 1. Prognostic Features of 10 transplant eligible patients
of MDS treated withoutHSCT:median age 62 yr (range 46-65)
No of Pts Prognostic features5 IPSS- Int-2 or High Risk
1 IPSS 0.5: Therapy related RCMD and Hb <80g/L
4 IPSS not known in 4: Blasts >10% -1; high risk
cytogenetics -1; Platelets 39 x109 -1; RCMD
and ANC 0.6 x109 -1.389
THROMBOTIC MICROANGIOPATHY WITH TACROLIMUS/SIROLIMUS-
BASED GVHD PROPHYLAXIS REGIMEN IN PATIENTS UNDERGOING HE-
MATOPOIETIC STEM CELL TRANSPLANT
Shayani, S.1, Palmer, J.2, Stiller, T.2, Rodriguez, R.3, Khuu, T.1,
Parker, P.M.4, Snyder, D.S.4, Pullarkat, V.4, Rosenthal, J.4,
Nademanee, A.4, Senitzer, D.4, Forman, S.J.4, Khaled, S.5,
Nakamura, R.4 1City of Hope National Medical Center, Duarte, CA;
2City of Hope National Medical Center, Duarte, CA; 3Kaiser Perma-
nente, Los Angeles, CA; 4City of Hope National Medical Center, Duarte,
CA; 5City of Hope National Medical Center, Duarte, CA
Thrombotic microangiopathy (TMA) is a multifactorial compli-
cation of allogeneic hematopoietic stem cell transplant (HCT).
The true incidence of TMA is difficult to estimate due to lack of
agreement on a single definition. Diagnosis is often complicated
by multiple potential etiologies for the clinical findings. Recently,
the addition of sirolimus (SIR) to tacrolimus (TAC) was reported
to result in a higher than expected incidence of TMA (Cutler et al.
BBMT 2005). We evaluated the incidence and risk factors for
TMA in patients who received allo-HCT using SIR/TAC-based
GVHD prophylaxis at City of Hope. TMA was defined as SCr in-
crease of $ 50% above baseline, LDH . 2x upper normal limit,
presence of schistocytes or persistent presence of nucleated RBCs,
and prolonged or progressive thrombocytopenia (\ 50 x 109/L or
$ 50% decrease). A case series of 183 patients who underwent sib-
ling donor (n 5 85) or MUD HCT (n 5 98) were included in this
study. The median age was 46 years (range: 10-70); Conditioning
regimens consisted of Flu/Mel (60%), FTBI/Cy or FTBI/VP16
(32%) and Bu/Cy (8%). Thirty-one (17%) patients met the above di-
agnostic criteria for TMAwithin the first 100 days post-HCT. In ad-
dition, we included 9 patients who did not meet the criteria due to
a missing test but were clinically diagnosed with TMA by indepen-
dent attending physicians, resulting in the total incidence of 22%
(40/183). Seven of the 40 patientsmet the criteria forTMA as a result
of ongoing multi-organ failure. The median time to TMA onset was
4.7 weeks (range: 1.6-12.6). Thirty-four patients developed both
TMA and aGVHD, in which the majority of patients (85%) devel-
oped TMA after a diagnosis of aGVHDhad beenmade. Themedian
of the median TAC and SIR levels over the first 30 days post HCT
were 8.9ng/ml (IQR: 7.7-10.2) and 6.5ng/ml (IQR: 5.2-8.6). Bymul-
tivariable analysis, we identified the following factors to be associated
with increased risk of TMA: 1) highest quartile of serum sirolimus
exposure: level $ 8.6 (HR: 2.52, 95%CI:0.99-6.39, p 5 0.05), 2)
aGVHD grades II-IV (HR: 3.43, 95%CI: 1.67-7.05, p\ 0.01), 3)
low-risk disease (HR: 1.92, 95%CI: 1.00-3.69, p5 0.05), and 4) fully
ablative conditioning (HR: 2.24, 95%CI: 1.16-4.34, p 5 0.02). In
